The Saltz article reviewed

ONCOLOGY

Volumn 19, Issue 9, 2005, Pages 1158-1160

  Sun, Weijing ^a   Haller, Daniel G ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ARTERY THROMBOSIS; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DIGESTIVE SYSTEM PERFORATION; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HYPERTENSION; METASTASIS; MONOTHERAPY; NOTE; OVERALL SURVIVAL; PROTEINURIA; QUALITY OF LIFE; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT; WOUND HEALING IMPAIRMENT;

EID: 33751074490     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (10)

1. Jemal A, Murray T, Ward E, et al: Cancer statistics, 2005. CA Cancer J Clin 55:10-30, 2005.
2. Saltz LB, Cox JV, Blanke CB, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343:905-914, 2000.
3. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004.
4. Tournigand C, Andre T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22:229-237, 2004.
5. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004.
6. Giantonio BJ, Catalano PJ, Meropol NJ, et al: High-dose bevacizumab in combination with FOLFOX4 in proves survival in patients with previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study 3200 (abstract A169). Proc Gastrointestinal Cancers Symposium, 2005, p 168.
7. Kabbinavar FF, Schulz J, McCleod M, et al: Bevacizumab (a monocolonal antibody to vascular endothelia growth factor) to prolong progression-free survival in first-line colorectal cancer (CRC) in subjects who are not suitable candidates for first-line CPT-11 (abstract 3516). Proc Am Soc Clin Oncol 23:249, 2004.
8. Avastin (bevacizumab) prescribing information - warning. December 2004.
9. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 35:337-345, 2004.
10. De Gramont A, Cervantes A, Andre T, et al: OPTIMOX study: FOLFOX7/LV5FU2 compared to FOLFOX4 in patients with advanced colorectal cancer (abstract 3525). Proc Am Soc Clin Oncol 23:251, 2004.